V
Valentina Magri
Researcher at Sapienza University of Rome
Publications - 32
Citations - 359
Valentina Magri is an academic researcher from Sapienza University of Rome. The author has contributed to research in topics: Internal medicine & Colorectal cancer. The author has an hindex of 9, co-authored 24 publications receiving 200 citations. Previous affiliations of Valentina Magri include Policlinico Umberto I.
Papers
More filters
Journal ArticleDOI
Automated classification of focal breast lesions according to S-detect: validation and role as a clinical and teaching tool
Mattia Di Segni,Valeria de Soccio,Vito Cantisani,Giacomo Bonito,Antonello Rubini,Gabriele Di Segni,Sveva Lamorte,Valentina Magri,Corrado De Vito,Giuseppe Migliara,Tommaso Vincenzo Bartolotta,Alessio Metere,Laura Giacomelli,Carlo de Felice,Ferdinando D'Ambrosio +14 more
TL;DR: S-detect is a feasible tool for the characterization of breast lesions; it has a potential as a teaching tool for more experienced operators and for the less experienced operators.
Journal ArticleDOI
T-DM1 Efficacy in Patients With HER2-positive Metastatic Breast Cancer Progressing After a Taxane Plus Pertuzumab and Trastuzumab: An Italian Multicenter Observational Study
Benedetta Conte,Alessandra Fabi,Francesca Poggio,Eva Blondeaux,Chiara Dellepiane,Alessia D'Alonzo,Giuseppe Buono,Grazia Arpino,Valentina Magri,Giuseppe Naso,Daniele Presti,Silvia Mura,Andrea Fontana,Francesco Cognetti,Chiara Molinelli,S. Pastorino,Claudia Bighin,Loredana Miglietta,Francesco Boccardo,Matteo Lambertini,Lucia Del Mastro +20 more
TL;DR: The results show meaningful activity of T-DM1 after front-line pertuzumab plus trastuzumAB and a taxane, with about 27% of patients having an objective response and 40% of Patients achieving durable disease control.
Journal ArticleDOI
Correlation of body composition by computerized tomography and metabolic parameters with survival of nivolumab-treated lung cancer patients.
Valentina Magri,Teodor Gottfried,Mattia Di Segni,Damien Urban,Michael Peled,Sameh Daher,Ronen Stoff,Jair Bar,Jair Bar,Amir Onn,Amir Onn +10 more
TL;DR: Weight loss and low albumin levels are significant negative prognostic factors for NSCLC patients on immunotherapy and CT-based parameters of body composition remain to be proven as more reliable than standard clinical parameters.
Journal ArticleDOI
A multicenter REtrospective observational study of first-line treatment with PERtuzumab, trastuzumab and taxanes for advanced HER2 positive breast cancer patients. RePer Study
Teresa Gamucci,Laura Pizzuti,Clara Natoli,Lucia Mentuccia,Isabella Sperduti,Maddalena Barba,Domenico Sergi,Laura Iezzi,Marcello Maugeri-Saccà,A. Vaccaro,Emanuela Magnolfi,Alain Gelibter,Giacomo Barchiesi,Valentina Magri,Loretta D'Onofrio,Alessandra Cassano,Ernesto Rossi,Andrea Botticelli,Luca Moscetti,Claudia Omarini,Maria Agnese Fabbri,A.F. Scinto,Domenico Corsi,Luisa Carbognin,Marco Mazzotta,Emilio Bria,Jennifer Foglietta,Riccardo Samaritani,Carlo Garufi,Luciano Mariani,Sandro Barni,Rosanna Mirabelli,Roberta Sarmiento,Vincenzo Graziano,Daniele Santini,Paolo Marchetti,Giuseppe Tonini,Luigi Di Lauro,Giuseppe Sanguineti,G. Paoletti,Silverio Tomao,Ruggero De Maria,Enzo Veltri,Ida Paris,Francesco Giotta,A Latorre,Antonio Giordano,Gennaro Ciliberto,Patrizia Vici +48 more
TL;DR: It is confirmed that trastuzumab/pertuzumAB/taxane is the standard of care as first-line treatment of patients with HER2-positive ABC even in the real-world setting.
Journal ArticleDOI
Circulating Tumor Cells in Right- and Left-Sided Colorectal Cancer
Chiara Nicolazzo,Cristina Raimondi,Angela Gradilone,Alessandra Emiliani,Ann Zeuner,Federica Francescangeli,Francesca Belardinilli,Patrizia Seminara,Flavia Loreni,Valentina Magri,Silverio Tomao,Paola Gazzaniga +11 more
TL;DR: The highest prognostic impact was exerted by CTC in left-sided primary cancer patients, even though the lowest median number of cells was detected in this subgroup of patients, which might imply a substantial difference in the biology of proximal and distal cancers, associated with different patterns of tumor cells dissemination.